Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-β is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-β on the other 20 members of the MMP family.
Methods
This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-β therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR.
Results
RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time.
Conclusions
These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-β in MS for at least 6 months.
1 Yong VW . Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology2002; 59: 802–808.
2.
2 Leppert D Waubant E Burk MR Oksenberg JR Hauser SL . Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol1996; 40: 846–852.
3.
3 Stuve O Dooley NP Uhm JH . Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol1996; 40: 853–863.
4.
4 Galboiz Y Shapiro S Lahat N Rawashdeh H Miller A . Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol2001; 50: 443–451.
5.
5 Galboiz Y Shapiro S Lahat N Miller A . Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis. J Neuroimmunol2002; 131: 191–200.
6.
6 Yong VW Power C Forsyth P Edwards DR . Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci2001; 2: 502–511.
7.
7 Leppert D Ford J Stabler G . Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain1998; 121: 2327–2334.
8.
8 Kieseier BC Kiefer R Clements JM . Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain1998; 121: 159–166.
9.
9 Anthony DC Miller KM Fearn S . Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol1998; 87: 62–72.
10.
10 Clements JM Cossins JA Wells GM . Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol1997; 74: 85–94.
11.
11 Hartung HP Kieseier BC . The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol2000; 107: 140–147.
12.
12 Yong VW . Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci2005; 6: 931–944.
13.
13 Gilli F Bertolotto A Sala A . Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain2004; 127: 259–268.
14.
14 Pugin J Widmer MC Kossodo S Liang CM Preas HL Suffredini AF . Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol1999; 20: 458–464.
15.
15 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–231.
16.
16 Bas A Forsberg G Hammarstrom S Hammarstrom ML . Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand J Immunol2004; 59: 566–573.
17.
17 Livak KJ Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods2001; 25: 402–408.
18.
18 Yuan JS Reed A Chen F Stewart CN . Statistical analysis of real-time PCR data. BMC Bioinformatics2006; 7: 85.
19.
19 Nichols T Hayasaka S . Controlling the familywise error rate in functional neuroimaging: a comparative review. Stat Methods Med Res2003; 12: 419–446.
20.
20 Waubant E Goodkin D Bostrom A . IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology2003; 60: 52–57.
21.
21 Trojano M Avolio C Liuzzi GM . Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology1999; 53: 1402–1408.
22.
22 Ozenci V Kouwenhoven M Teleshova N Pashenkov M Fredrikson S Link H . Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol2000; 108: 236–243.
23.
23 Karabudak R Kurne A Guc D Sengelen M Canpinar H Kansu E . Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol2004; 251: 279–283.
24.
24 Jung K . Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers. Transplantation2005; 79: 744.
25.
25 Gerlach RF Demacq C Jung K Tanus-Santos JE . Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem2007; 25: 4960–4966.
26.
26 Ma ZD Qin HW Benveniste EN . Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: Critical role of STAT-1 alpha. J Immunol2001; 167: 5150–5159.
27.
27 Der SD Zhou A Williams BR Silverman RH . Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA1998; 95: 15623–15628.
28.
28 Ramanathan M Weinstock-Guttman B Nguyen LT . In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol2001; 116: 213–219.
29.
29 van Horssen J Vos CM Admiraal L . Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol Appl Neurobiol2006; 32: 585–593.
30.
30 Stracke JO Hutton M Stewart M . Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem2000; 275: 14809–14816.
31.
31 Mauch S Kolb C Kolb B Sadowski T Sedlacek R . Matrix metalloproteinase-19 is expressed in myeloid cells in an adhesion-dependent manner and associates with the cell surface. J Immunol2002; 168: 1244–1251.
32.
32 Bar-Or A Nuttall RK Duddy M . Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain2003; 126: 2738–2749.
33.
33 Sadowski T Dietrich S Koschinsky F Sedlacek R . Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell2003; 14: 4569–4580.
34.
34 Matias-Roman S Galvez BG Genis L . Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood2005; 105: 3956–3964.
